Michael Dickinson, MBBS, DMedSc, on ASH Glofitamab Updates

By Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA - Last Updated: February 3, 2023

Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, of the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, discusses updates on glofitamab, a bispecific antibody for the treatment of relapsed or refractory diffuse large B-cell lymphoma, that were presented during the 2022 American Society Hematology Annual Meeting.

What Is the Optimal Treatment Sequence for Relapsed or Refractory T-Cell Lymphoma?

Melissa BadamoT-Cell Lymphoma | April 3, 2025

Mark Sorial, PharmD, BCOP, shared the latest research from the Salvia Jain Lab's PETAL Consortium.

Urvi Shah, MD, Highlights the Significance and Limitations of Observational Nutritional Studies

Urvi A. Shah, MDMyeloma | March 27, 2025

Dr. Shah discusses the significance and limitations of two studies on dietary factors and risk of myeloma and MGUS.

Study Identifies Dietary Risk Factors for Myeloma

Francesca Castro, MS, RDN, CDNMyeloma | March 26, 2025

A plant-based diet is significantly associated with a reduced risk of multiple myeloma.

What Are the Dietary Risk Factors for MGUS?

Janine Joseph, MS, MBAMyeloma | March 24, 2025

A US population-based study investigated the associations between MGUS and various dietary patterns.

What Does the Future Hold for DLBCL Care? What Direction Should New Research Take?

Tara Graff, DO, MSAggressive B-Cell Lymphoma | March 10, 2025

The expert panel describes outstanding clinical research needs in DLBCL and what research underway they find exciting.

Michael Dickinson, MBBS, DMedSc, on ASH Glofitamab Updates

Related Posts